Sanofi Partners with Belharra to Tackle ‘Undruggable’ Immunology Targets in $700M Deal

1. Partnership Details: Sanofi and Belharra Therapeutics have entered a strategic partnership worth up to $700 million to develop small molecule therapies for immunological diseases.
2. Belharra's Role: Belharra will utilize its proprietary chemoproteomics platform to identify and validate targets selected by Sanofi, focusing on previously 'undruggable' targets.
3. Financial Terms: Belharra will receive an upfront payment of $40 million and is eligible for additional payments of up to $700 million, including research, development, commercial milestones, and royalties.
4. Sanofi's Objectives: Sanofi aims to strengthen its presence in immunology and small molecule treatments, leveraging Belharra's platform to explore new therapeutic opportunities.
5. Belharra's Platform: The company's platform is designed to provide comprehensive and unbiased chemoproteomic screening capabilities, identifying binding pockets on proteins and protein-protein interactions across various cell types.
6. Previous Partnerships: Belharra has a multi-year partnership with Roche Group member Genentech for immuno-oncology, oncology, neurodegenerative, and autoimmune diseases, and Sanofi has collaborated with IGM Biosciences for immunoglobin M (IgM) agonist antibody development.